Global Clinical Trials Market Size, Share, Growth Trends, and Forecast, 2026-2035 | Clinical Trials Market set to more than Double to $144.4bn as Drugmakers Lean on Outside Researchers

Dublin, Oct. 23, 2026 -- "Clinical Trials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

Clinical trials remain integral to drug development, safety and efficacy assessment, and regulatory approval across major therapeutic areas. The increasing complexity of drug pipelines, particularly in biologics, oncology, rare diseases, and precision medicine, is generating demand for sophisticated clinical research services and advanced study methodologies. Digital tools, decentralized trial models, AI-driven analytics, and real-world evidence integration are also improving patient recruitment, data quality, monitoring capabilities, and operational efficiency.

Interventional Studies Support Market Expansion

Based on study design, the interventional study segment is expected to grow at a CAGR of 8.5% through 2035. Its expansion is driven by the central role of interventional trials in regulatory submissions and clinical evidence generation. These studies are widely used across drug, biologic, and medical device development to produce robust data on treatment safety and efficacy.

Interventional trials increasingly incorporate adaptive trial designs, precision medicine strategies, electronic data capture, remote monitoring, and AI-powered analytics. These capabilities help sponsors improve scalability, preserve data integrity, and optimize trial timelines, reinforcing the segment's leading position in the Global Clinical Trials Market.

Oncology Leads Clinical Trial Activity

The oncology segment accounted for 38.3% of the market in 2025, reflecting the rising global cancer burden and strong investment in cancer drug development. Growing incidence rates, aging populations, and persistent unmet clinical needs continue to support oncology-focused R&D worldwide.

Oncology clinical trials are becoming more specialized through the adoption of biomarkers, companion diagnostics, and precision medicine strategies. A high volume of oncology drug approvals, fast-track designations, and continued innovation in targeted therapies and biologics further strengthens the segment's contribution to clinical trial market growth.

North America Maintains Market Leadership

North America held 50.7% of the Global Clinical Trials Market in 2025. The region's leadership is supported by advanced research infrastructure, a high concentration of pharmaceutical and biotechnology companies, qualified investigators, specialized trial sites, and an established regulatory framework.

Strong public funding, including investments from the National Institutes of Health, continues to advance clinical research across oncology, rare diseases, and other high-priority therapeutic areas. Increasing outsourcing to Contract Research Organizations (CROs) is also enabling sponsors to access specialized expertise, technology platforms, and scalable trial management capabilities.

Competitive Landscape and Strategic Priorities

Key companies operating in the Global Clinical Trials Market include IQVIA Holdings Inc., ICON plc, Laboratory Corporation of America Holdings (Covance Inc.), Charles River Laboratories International, Inc., Parexel International Corporation, Syneos Health, Medpace, SGS SA, WuXi AppTec Co., Ltd., Worldwide Clinical Trials, ClinChoice, Celerion, Veeda, Qserve, The Emmes Company, and Pharmaceutical Product Development (Thermo Fisher Scientific).

Market participants are strengthening their positions through strategic outsourcing, geographic expansion, partnerships, and technology-driven service innovation. Investments in decentralized and hybrid trial solutions, digital platforms, remote patient monitoring, and AI-based analytics are helping accelerate study timelines and improve patient engagement. Collaborations with pharmaceutical sponsors, biotechnology firms, and academic institutions are expanding therapeutic expertise and access to diverse patient populations. Companies are also increasing their presence in high-growth Asia Pacific markets to benefit from cost efficiencies, expanding research capabilities, and faster patient recruitment.

Comprehensive Market Analysis and Forecast

• Industry trends, growth drivers, market challenges, future opportunities, and regulatory developments
• Competitive landscape assessment using Porter's Five Forces and PESTEL analysis
• Clinical trials market size, study design segmentation, therapeutic area analysis, and regional forecasts
• In-depth company profiles, business strategies, financial insights, and SWOT analysis

Key Topics Covered:

Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy and data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Revenue share analysis
1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust

Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Phase trends
2.2.3 Study design trends
2.2.4 Therapeutic area trends
2.2.5 Service type trends
2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases across the globe
3.2.1.2 Growing demand for outsourcing clinical trials to CROs
3.2.1.3 Rise in government and non-government funding for clinical trials
3.2.1.4 Growing opportunities for conducting clinical trials in countries in Asia-Pacific
3.2.2 Industry pitfalls and challenges
3.2.2.1 Lack of standard-of-care coverage from insurance providers
3.2.2.2 Infrastructural barriers and social hurdles
3.2.3 Market opportunities
3.2.3.1 Growth of decentralized clinical trials (DCTs)
3.2.3.2 Integration of artificial intelligence and advanced analytics
3.3 Clinical trials volume analysis (Driven by Primary Research)
3.3.1 Clinical trials volume analysis, by region, 2022-2025
3.3.2 Clinical trials volume analysis, by phase of development, 2022-2025
3.3.3 Clinical trials volume analysis, by indication, 2022-2025
3.4 Regulatory landscape (Driven by Primary Research)
3.4.1 U.S.
3.4.2 Europe
3.4.3 Asia-Pacific
3.4.3.1 Singapore
3.4.3.2 Malaysia
3.4.3.3 Indonesia
3.4.3.4 Thailand
3.4.3.5 South Korea
3.4.3.6 Philippines
3.5 Clinical trials - Asia-Pacific advantage (Driven by Primary Research)
3.6 Impact of AI and Gen AI on the market
3.7 Porters analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, by Phase, 2022-2035 ($ Mn)
5.1 Key trends
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV

Chapter 6 Market Estimates and Forecast, by Study Design, 2022-2035 ($ Mn)
6.1 Key trends
6.2 Interventional study
6.3 Observational study
6.4 Expanded access study

Chapter 7 Market Estimates and Forecast, by Therapeutic Area, 2022-2035 ($ Mn)
7.1 Key trends
7.2 Autoimmune disease
7.3 Oncology
7.4 Cardiology
7.5 Infectious disease
7.6 Dermatology
7.7 Ophthalmology
7.8 Neurology
7.9 Hematology
7.10 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, by Service Type, 2022-2035 ($ Mn)
8.1 Key trends
8.2 Outsourcing service
8.3 In-house service

Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Netherlands
9.3.8 Switzerland
9.3.9 Russia
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Singapore
9.4.7 Malaysia
9.4.8 Indonesia
9.4.9 Thailand
9.4.10 Philippines
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Colombia
9.5.5 Peru
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE

Chapter 10 Company Profiles
10.1 Cadiya (Clinipace)
10.2 Celerio
10.3 Charles River Laboratories
10.4 ClinChoice
10.5 ICON plc
10.6 IQVIA HOLDINGS
10.7 Labcorp Holding (Covance)
10.8 Medpace
10.9 Parexel International Corporation
10.10 Pharmaceutical Product Development (Thermo Fisher Scientific)
10.11 Qserve
10.12 SGS SA
10.13 Syneos Health
10.14 The Emmes Company
10.15 Veeda
10.16 Worldwide Clinical Trials
10.17 Wuxi AppTec Co.

For more information about this report visit https://www.researchandmarkets.com/r/p166we

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.